---
figid: PMC1208922__1477-3163-4-16-1
figtitle: EGFR/MAPK/ERK1/2 signaling pathway
organisms:
- NA
pmcid: PMC1208922
filename: 1477-3163-4-16-1.jpg
figlink: /pmc/articles/PMC1208922/figure/F1/
number: F1
caption: The EGFR/MAPK/ERK1/2 signaling pathway. We have previously shown that sulindac
  metabolites inhibit both MEK1/2 and ERK1/2 activation. The goal of this study was
  to determine if this inhibition is due to downregulation of the EGFR.
papertitle: Sulindac metabolites inhibit epidermal growth factor receptor activation
  and expression.
reftext: Heather A Pangburn, et al. J Carcinog. 2005;4:16-16.
year: '2005'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8338524
figid_alias: PMC1208922__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC1208922__F1
ndex: 8657adbd-df1d-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC1208922__1477-3163-4-16-1.html
  '@type': Dataset
  description: The EGFR/MAPK/ERK1/2 signaling pathway. We have previously shown that
    sulindac metabolites inhibit both MEK1/2 and ERK1/2 activation. The goal of this
    study was to determine if this inhibition is due to downregulation of the EGFR.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - EGFR
  - MAPK3
  - MAPK1
  - KRAS
  - HRAS
  - NRAS
  - RAF1
  - MAP2K1
  - MAP2K2
  - Egfr
  - rl
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Sulindac
  - Cancer
---
